Novel Infusion Pump Allows Drug Delivery During MRI Scans
By HospiMedica International staff writers Posted on 04 Jan 2017 |
Image: The MRidium 3860+ infusion pump system allows patients to undergo MRI procedures (Photo courtesy of Iradimed).
A novel infusion pump compatible with magnetic resonance imaging (MRI) devices enables patients dependent on intravenous (IV) medication to undergo scanning.
The MRidium 3860+ infusion pump system is designed to provide a seamless approach that enables accurate, safe, and dependable IV medication and fluid delivery before, during, and after an MRI scan. A broad range of infusion rates support differing patient needs, including low levels for sedating children and infants in order to immobilize them during an MRI scan, mid-levels for continued IV infusion of medications to critically-ill patients, and high levels in the event of emergency situations.
The system incorporates a non-magnetic motor with a broad range of fluid flow control--from 0.1 to 1,400 mL per hour in order--to ensure the safe and predictable delivery of IV fluids during the MRI procedure. The IV infusion pump system also includes a proprietary single-use IV tubing sets, a non-magnetic pole, and a lithium battery, allowing it to be operated dependably in the presence of 0.2T to 3T magnets, up to a fully operational 10,000 gauss-line. Optional upgrades include a remote control, a sidecar, and an oxygen saturation pulse oximetry (SpO2) monitor.
The device also includes dose error reduction system (DERS) software, which enables users to create a unique drug library and establish nominal values and limits for dose and concentration for specified infusion protocols. With DERS, patient safety and user convenience are supported by user-programmed infusion hard (maximum and minimum) and soft (user confirmed) limits. The MRidium 3860+ infusion pump system is a product Iradimed (Winter Springs, FL, USA), and has been approved by the U.S. Food and Drug Administration (FDA).
“We have demonstrated that our IV pump and development processes meet the high standards established by FDA,” said Roger Susi, President and Chief Executive Officer of the Company. “With this clearance behind us, we are now able to allocate our full resources to finalizing the development of our MRI compatible patient vital signs monitoring system, and continue planning for its successful launch.”
Related Links:
Iradimed
The MRidium 3860+ infusion pump system is designed to provide a seamless approach that enables accurate, safe, and dependable IV medication and fluid delivery before, during, and after an MRI scan. A broad range of infusion rates support differing patient needs, including low levels for sedating children and infants in order to immobilize them during an MRI scan, mid-levels for continued IV infusion of medications to critically-ill patients, and high levels in the event of emergency situations.
The system incorporates a non-magnetic motor with a broad range of fluid flow control--from 0.1 to 1,400 mL per hour in order--to ensure the safe and predictable delivery of IV fluids during the MRI procedure. The IV infusion pump system also includes a proprietary single-use IV tubing sets, a non-magnetic pole, and a lithium battery, allowing it to be operated dependably in the presence of 0.2T to 3T magnets, up to a fully operational 10,000 gauss-line. Optional upgrades include a remote control, a sidecar, and an oxygen saturation pulse oximetry (SpO2) monitor.
The device also includes dose error reduction system (DERS) software, which enables users to create a unique drug library and establish nominal values and limits for dose and concentration for specified infusion protocols. With DERS, patient safety and user convenience are supported by user-programmed infusion hard (maximum and minimum) and soft (user confirmed) limits. The MRidium 3860+ infusion pump system is a product Iradimed (Winter Springs, FL, USA), and has been approved by the U.S. Food and Drug Administration (FDA).
“We have demonstrated that our IV pump and development processes meet the high standards established by FDA,” said Roger Susi, President and Chief Executive Officer of the Company. “With this clearance behind us, we are now able to allocate our full resources to finalizing the development of our MRI compatible patient vital signs monitoring system, and continue planning for its successful launch.”
Related Links:
Iradimed
Latest Critical Care News
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration